Kadcyla: why breast cancer drug won't be on the NHS

Another 'huge blow' to cancer patients, as campaigners call on drug companies to bring down costs

Doctors look at films of breast cancer X-rays
(Image credit: Justin Sullivan/Getty Images)

A "revolutionary" new breast cancer treatment will not be available on the NHS due to its high cost, the government's drug regulator has announced.

The National Institute for Health and Care Excellence (Nice) said it could not recommend Kadcyla, one of the most expensive cancer drugs sold in England, to the NHS because it was not cost effective.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us